This is a routine proxy filing with no financial results or strategic updates. The equity grants are modest relative to market cap and standard for annual director/CEO compensation. No actionable trading signal — monitor the 20-F annual report for financial performance and any material business updates.
Price Chart
Executive Summary
BrainsWay filed a 6-K containing its proxy statement for the November 25, 2026 annual general meeting. The agenda includes routine items: re-appointment of auditors, re-election of seven directors, and approval of RSU grants to the CEO (60,000 RSUs, ~$693,000 fair value) and six non-executive directors (17,500 RSUs each, ~$202,125 each). No financial results or material business developments are disclosed, making this a routine governance filing with no immediate stock-moving catalyst.
Key Facts
- Annual general meeting scheduled for November 25, 2026, with record date of October 26, 2026.
- Proposal to re-appoint Kost Forer Gabbay & Kasierer (EY) as independent auditors for 2026; audit fees for 2025 were $515,000.
- Seven directors nominated for re-election: Ami Boehm (Chairman), Dr. David Zacut (Vice Chairman), Eti Mitrany, Karen Sarid, Prof. Abraham Zangen, Avner Lushi, and Jonathan Shulkin.
- CEO Hadar Levy proposed to receive 60,000 RSUs with an aggregate fair market value of approximately $693,000, vesting over 3.5 years.
- Each of six non-executive directors proposed to receive 17,500 RSUs with an aggregate fair market value of approximately $202,125 per director, vesting over 3.5 years.
- Outstanding ordinary shares as of record date: 40,252,989.
Financial Impact
CEO RSU grant valued at ~$693,000; director RSU grants total ~$1,212,750 (6 × $202,125). Combined ~$1.9M in new equity compensation, representing ~0.4% of market cap ($481M). Immaterial dilution.
Risk Factors
- No financial data or guidance provided — filing offers no insight into operational trends.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006741 |
| Exhibit: exh_992.htm | 0001171843-26-006741 |
| Document: f6k_102026.htm | 0001171843-26-006741 |
| Document: 0001171843-26-006741-index-headers.html | 0001171843-26-006741 |
| Document: 0001171843-26-006741-index.html | 0001171843-26-006741 |
| Document: 0001171843-26-006741.txt | 0001171843-26-006741 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+60 | — | — |
Oct 21, 2026 4d ago | 6-K | $11.44 | awaiting T+60 | — | $11.18 (−2.27%) |
Oct 19, 2026 6d ago | 6-K | $11.99 | awaiting T+60 | — | $11.18 (−6.76%) |
Oct 19, 2026 7d ago | Press Release | $11.99 | awaiting T+60 | — | $11.18 (−6.76%) |
Oct 13, 2026 13d ago | 6-K | $11.92 | awaiting T+60 | — | $11.18 (−6.21%) |
Sep 8, 2026 6w ago | 6-K | $14.16 | awaiting T+60 | — | $11.18 (−21.05%) |
Aug 27, 2026 8w ago | 6-K | $14.40 | awaiting T+60 | — | $11.18 (−22.36%) |
Aug 12, 2026 10w ago | 6-K | $16.47 | awaiting T+60 | — | $11.18 (−32.12%) |
Aug 12, 2026 10w ago | 6-K | $16.60 | awaiting T+60 | — | $11.18 (−32.65%) |
Aug 12, 2026 10w ago | Press Release | $16.60 | awaiting T+60 | — | $11.18 (−32.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers